Figure 2 — Mutations in DNA damage response pathways as a potential biomarker for immune checkpoint blockade efficacy: evidence from a seven-cancer immunotherapy cohort

Research Paper|Volume 13, Issue 21|pp. 24136–24154

Mutations in DNA damage response pathways as a potential biomarker for immune checkpoint blockade efficacy: evidence from a seven-cancer immunotherapy cohort

Back to articleFigure 2(2 of 6)

100%

Figure 2.Association of DDR mutations with survival outcome in MSKCC and TCGA cohorts. (A–B) DDR mutations versus survival outcome with univariate analysis and multivariate regression model in the MSKCC cohort; (C–D) DDR mutations versus survival outcome with univariate analysis and multivariate regression model in the TCGA cohort.